A5014337725- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Global Cancer Incidence and Screening
- Cytokine Signaling Pathways and Interactions
- Statistical Methods in Clinical Trials
- Clinical practice guidelines implementation
- Mass Spectrometry Techniques and Applications
- Cancer-related Molecular Pathways
- Monoclonal and Polyclonal Antibodies Research
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Cancer, Lipids, and Metabolism
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer survivorship and care
- Radiation Therapy and Dosimetry
- Colorectal Cancer Screening and Detection
- PARP inhibition in cancer therapy
- Advanced Radiotherapy Techniques
- Immunotherapy and Immune Responses
- Patient Satisfaction in Healthcare
- Male Breast Health Studies
Lund University
2014-2025
Bayer (Germany)
2023-2024
Skåne University Hospital
2015-2020
University of California, Los Angeles
2016-2018
Malmö University
2015
Cancer Genetics (United States)
2012-2013
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). Rational combination therapies may improve treatment efficacy. Here, we explored the effect of androgen receptor blockade (ARB) on PSMA expression visualized by PET and its potential additive when combined with 177Lu-PSMA RLT mouse model cancer. Mice bearing human CRPC (C4-2 cells) xenografts were treated 10 mg/kg...
Prostate cancer patients with high WNT5A expression in their tumors have been shown to more favorable prognosis than those low expression. This suggests that reconstitution of Wnt5a WNT5A-expressing might be an attractive therapeutic approach. To explore this idea, we the present study used Foxy-5, a mimicking peptide, investigate its impact on primary tumor and metastasis vivo prostate cell viability, apoptosis invasion vitro. We orthotopic xenograft mouse model metastatic...
Abstract Background and Purpose Malignant melanoma is the most lethal form of skin cancer, characterised by a poor survival rate. One key factors driving aggressive growth cells elevated expression proto‐oncogene Bcl‐3. This study aims to optimise, evaluate characterise second‐generation Bcl‐3 inhibitor, using as model demonstrate its potential therapeutic efficacy. Experimental Approach We synthesised screened series structural analogues selected A27, promising candidate for further...
Abstract Despite new therapies, castration-resistant prostate cancer (CRPC) is still incurable. Intercellular Adhesion Molecule 1 (ICAM-1) a well-characterized cell surface protein involved in pathogenesis, differentially expressed during transition from hormone-sensitive to CRPC. This study aimed investigate ICAM-1 as target for imaging and radioimmunotherapy of Anti-ICAM-1 antibody R6.5 was labeled with 111In or 177Lu, non-specific 177Lu. In vitro uptake tested PC-3 cells. Biodistribution...
Clinical <sup>177</sup>Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced-stage prostate cancer. However, to the best of our knowledge murine models study biologic effects various activity levels have not been established. The aim this was optimize specific and total for RLT a syngeneic model <b>Methods:</b> Murine-reconstituted, oncogene-driven cancer cells (0.1 × 10<sup>6</sup>) (RM1), transduced express human prostate-specific membrane antigen (PSMA), were injected into left...
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is effective against prostate cancer (PCa), but all patients relapse eventually. Poor understanding of the underlying resistance mechanisms represents a key barrier to development more RLT. We investigate proteome and phosphoproteome in mouse model PCa identify signaling adaptations triggered by PSMA
There is an urgent need for new treatment options in metastatic drug-resistant prostate cancer. Combining immunotherapy with other targeted therapies may be effective strategy advanced In the present study, we sought to investigate enhance efficacy of anti-CTLA-4 therapy against cancer by combination STAT3 inhibition.Male C57BL6 mice were subcutaneously inoculated murine cell line RM-1. Tumor progression was monitored following vehicle, small molecule inhibitor GPB730, or GPB730 +...
The transcription factor STAT3 is a potential target for the treatment of castration-resistant prostate cancer. Galiellalactone (1), direct inhibitor STAT3, prevents regulated genes. In this study we characterized 6 (GPA512, Johansson, M.; Sterner, O. Patent WO 2015/132396 A1, 2015), prodrug 1. vitro studies showed that rapidly converted to 1 in plasma and stable buffer solution. pharmacokinetics following single oral dose indicated was absorbed with tmax 15 min. Oral administration mice...
Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, to wait until palliative treatment needed. PIONEER, funded by European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through application big data analytics. To describe clinical characteristics and long-term outcomes on conservative using international large network real-world data. From initial cohort >100 000...
Ac-PSMA-617 targeted-therapy has demonstrated efficacy in 75-85% of patients; however, responses are not durable. We aimed to establish translatable mouse models disseminated prostate cancer (PCa) evaluate effectiveness
Combination therapies in metastatic hormone-sensitive prostate cancer (mHSPC), which include the addition of an androgen receptor signaling inhibitor and/or docetaxel to deprivation therapy, have been a game changer management this disease stage. However, these come with their fair share toxicities and side effects. The goal observational study is report drug-related adverse events (AEs), are correlated systemic combination for mHSPC. Determining optimal treatment option requires large...
Once prostate cancer becomes castration resistant, cells may rapidly gain the ability to invade and metastasize lymph nodes distant organs. The progression through hormone-dependent hormone-independent/castration-resistant metastatic PCa is poorly understood. In this review paper, we provide an overview on cellular molecular mechanisms underlying process of tumor cell invasion metastasis in cancer. We specifically present most recent findings role multiple signaling pathways including...
Prostate cancer is a leading cause of death in the male population western world. Human kallikrein-related peptidase 2 (hK2) abundantly expressed malignant prostatic tissue, and its gene, KLK2, regulated by androgen receptor. 11B6 murine IgG1 monoclonal antibody directed against free human hK2. In this study, we performed preclinical evaluation (111)In-labelled mouse xenografts to investigate potential clinical staging assessment metastatic prostate cancer.11B6 was radiolabelled with (111)In...
The ability of health care professionals to communicate with patients compassionately and effectively is crucial for shared decision-making, but little research has investigated patient-clinician communication. As part PIONEER—an international Big Data Consortium led by the European Association Urology answer key questions men prostate cancer (PCa), funded through IMI2 Joint Undertaking under grant agreement 777492— we communication between diagnosed PCa professional(s) treating them across...